Comparison of the variability of the annual rates of change in FEV 1 determined from serial measurements of the pre- versus post-bronchodilator FEV 1 over 5 years in mild to moderate COPD: Results of the lung health study

Respiratory Research

Volumn 13, Issue , 2012, Pages

  Tashkin, Donald P ^a   Wang, He Jing ^a   Halpin, David ^b   Kleerup, Eric C ^a   Connett, John ^c   Li, Ning ^a   Elashoff, Robert ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ROYAL DEVON AND EXETER HOSPITAL   (United Kingdom)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Chronic obstructive pulmonary disease (COPD); FEV 1 decline; Lung health study; Post bronchodilator; Pre bronchodilator

Indexed keywords

BRONCHODILATING AGENT; ISOPRENALINE;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; SMOKING; SPIROMETRY; TREATMENT DURATION; TREATMENT RESPONSE; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; HEALTH STATUS; LUNG; LUNG FUNCTION TEST; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; TIME;

ADULT; BRONCHODILATOR AGENTS; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HUMANS; LUNG; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS; TIME FACTORS;

EID: 84864954336     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-13-70     Document Type: Article

References (32)

1. Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J 1977, 1:1645-1648. 10.1136/bmj.1.6077.1645, 1607732, 871704.
2. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2010, http://www.goldcopd.org.
3. Casanova C, de Torres JP, Aguirre-Jaime A, Pinto-Plata V, Marin JM, Cordoba E, BAz R, kKCote C, Celli BR. The progression of chronic obstructive pulmonary disease is heterogeneous. The experience of the BODE cohort. Am J Respir Crit Care Med 2011, 184:1015-1021. 10.1164/rccm.201105-0831OC, 21836135.
4. Detels R, Tashkin DP, Sayre JW, Rokaw SN, Massey FJ, Coulson AH, Wegman DH. The UCLA population studies of CORD. X. A cohort study of changes in respiratory function associated with chronic exposure to SOX, NOX and hydrocarbons. Am J Public Health 1991, 81:350-359. 10.2105/AJPH.81.3.350, 1405012, 1994744.
5. Tashkin DP, Detels R, Simmons M, Liu H, Coulson AH, Sayre J, Rokaw S. The UCLA Population Studies of Chronic Obstructive Respiratory Disease XI. Impact of air pollution and smoking on annual change in forced expiratory volume in one second. Am J Respir Crit Care Med 1994, 149:1209-1217.
6. Kohansal R, Martinez-Camblor P, Agusti A, Buist AS, Mannino DM, Soriano JB. The natural history of chronic airflow obstruction revised. An analysis of the Framingham Offsping Cohort. Am J Respir Crit Care Med 2009, 180:3-10. 10.1164/rccm.200901-0047OC, 19342411.
7. Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, Conway WA, Enright PL, Kanner RE, O'Hara P, Owens GR, Scanlon PD, Tashkin DP, Wise RA, , . for the Lung Health Study Research Group, for the Lung Health Study Research Group Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994, 272:1497-1505. 10.1001/jama.1994.03520190043033, 7966841, for the Lung Health Study Research Group, for the Lung Health Study Research Group.
8. Scanlon PD, Connett JE, Waller LA, Altose MD, Bailey WC, Buist AS, Tashkin DP, , . for the Lung Health Study Research Group, for the Lung Health Study Research Group Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease: the lung health study. Am J Respir Crit Care Med 2000, 161:381-390. for the Lung Health Study Research Group, for the Lung Health Study Research Group.
9. Pauwels RA, Lofdahl C-G, Laitinen LA, Schouten JP, Postma DS, Pride NB, Ohlsson SV. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Eng J Med 1999, 340:1948-1953.
10. Burge PS, Calverley PMA, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double-blind, placebo-controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000, 320:1297-1303. 10.1136/bmj.320.7245.1297, 27372, 10807619.
11. Vesto J, Sorensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide im mild and moderate chronic obstructive pulmonary disease: a randomized controlled trial. Lancet 1999, 353:1819-1823. 10.1016/S0140-6736(98)10019-3, 10359405.
12. The Lung Health Study Research Group Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000, 343:1902-1909. The Lung Health Study Research Group.
13. Decramer M, Rutten-van Molken M, Dekhuijzen PNR, Troosters T, van Herwaarden C, Pellegrino R, van Schayck CPO, Olivieri D, Del Donno M, De Backer W, Lankhorst I, Ardia A. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomized placebo-controlled trial. Lancet 2005, 365:1552-1560. 10.1016/S0140-6736(05)66456-2, 15866309.
14. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M, , . for the UPLIFT study investigators, for the UPLIFT study investigators A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008, 359:1543-1554. 10.1056/NEJMoa0805800, 18836213, for the UPLIFT study investigators, for the UPLIFT study investigators.
15. Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, Vestbo J, Knobil K, Yates JC, Calverley PMA. Effect of pharmacotherapy on rate of decline in lung function in chronic obstructive pulmonary disease. Results from the TORCH study. Am J Respir Crit Care Med 2008, 178:332-338. 10.1164/rccm.200712-1869OC, 18511702.
16. Postma DS, Hoeter GH, vd Mark TW, Reig RP, Sluiter HJ. The effects of oral slow-release terbutaline on the circadian variation in spirometry and arterial blood gas levels in patients with chronic airflow obstruction. Chest 1985, 87:653-657. 10.1378/chest.87.5.653, 3987377.
17. Pennock BE, Rogers RM, McCaffree DR. Changes in measured spirometric indices. What is significant?. Chest 1981, 80:97-99. 10.1378/chest.80.1.97, 7249720.
18. Nisar M, Earis JE, Pearson MG, Calverley PMA. Acute bronchodilator trials in chronic obstructive pulmonary disease. Am Rev Respir Dis 1991, 146:555-559.
19. Enright PL, Johnson LR, Connett JE, voelker H, Buist AS. Spirometry in the Lung Health Study: I. Methods and quality control. Am Rev Respir Dis 1991, 143:1215-1233.
20. Tashkin DP, Altose MD, Bleecker ER, Connett JE, Kanner RE, Lee WW, Wise R, , . for the Lung Health Study Research Group, for the Lung Health Study Research Group The Lung Health Study: Airway responsiveness to inhaled methacholine in smokers with mild to moderate airflow limitation. Am Rev Respir Dis 1992, 145:301-310. for the Lung Health Study Research Group, for the Lung Health Study Research Group.
21. Crapo RD, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 1981, 123:659-664.
22. O'Connor GT, Sparrow D, Weiss ST. A prospective longitudinal study of methacholine airway responsiveness as a predictor of pulmonary function decline: the Normative Aging Study. Am J Respir Crit Care Med 1995, 152:87-92.
23. Calverley PMA, Lee A, Towse L, van Noord J, Witeck TJ, Kelsen S. Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease. Thorax 2003, 58:855-860. 10.1136/thorax.58.10.855, 1746483, 14514937.
24. van Noord JA, Aumann JL, Janssens E, Verhaert J, Smeets JJ, Meuller A, Cornelissen PJG. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006, 129:509-517. 10.1378/chest.129.3.509, 16537846.
25. Tashkin DP. Measurement and Significance of the Bronchodilator Response. Bronchodilators: Theory and Practice 1987, 535-613. Marcel Dekker, Inc, New York, Jenne JW.
26. Calverley PMA, Burge PS, Spencer S, Anderson JA, Jones PW, , . for the ISOLDE Study Investigators, for the ISOLDE Study Investigators Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 2003, 58:659-664. 10.1136/thorax.58.8.659, 1746778, 12885978, for the ISOLDE Study Investigators, for the ISOLDE Study Investigators.
27. Dorinsky PM, Reisner C, Ferguson GT, Menjoge SS, Serby CW, Witek TJ. The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD. Chest 1999, 115:966-971. 10.1378/chest.115.4.966, 10208193.
28. Tashkin DP, Celli B, Decramer M, Liu D, Burkhart D, Cassino C, Kesten S. Bronchodilator responsiveness in patients with COPD. Eur Respir J 2008, 31:742-750. 10.1183/09031936.00129607, 18256071.
29. Celli B, Tashkin DP, Rennard SI, McElhattan J, Martin U. Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in patients with COPD. Respir Med 2011, 105:1176-1188. 10.1016/j.rmed.2011.02.020, 21531124.
30. Anthonisen NR, Lindgren PG, Tashkin DP, Kanner RE, Scanlon PD, Connett JE. Bronchodilator response in mild to moderate COPD over 11 years: Results from the Lung Health Study. Eur Respir J 2005, 26:45-51. 10.1183/09031936.05.00102604, 15994388.
31. DuBois AB. Resistance to breathing. Handbook of Physiology, Section 3: Respiration, vol 1 1964, 451-452. American Physiological Society, Washington, DC, Fenn WO, Rahn H.
32. Mannino DM, Diaz-Guzman E, Buist S. Pre- and post-bronchodilator lung function as predictors of mortality in the Lung Health Study. Respir Res 2011 Oct 12, 12:136.